These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
251 related articles for article (PubMed ID: 35836532)
1. N6-methyladenosine methylation related immune biomarkers correlates with clinicopathological characteristics and prognosis in clear cell renal cell carcinoma. Huang Z; Kang W; Zhang Q Transl Cancer Res; 2022 Jun; 11(6):1576-1586. PubMed ID: 35836532 [TBL] [Abstract][Full Text] [Related]
2. Integrated analysis on the N6-methyladenosine-related long noncoding RNAs prognostic signature, immune checkpoints, and immune cell infiltration in clear cell renal cell carcinoma. Qiu Y; Wang X; Fan Z; Zhan S; Jiang X; Huang J Immun Inflamm Dis; 2021 Dec; 9(4):1596-1612. PubMed ID: 34432955 [TBL] [Abstract][Full Text] [Related]
3. Construction and validation of an m6A RNA methylation regulator prognostic model for early-stage clear cell renal cell carcinoma. Wang Z; Zhang M; Seery S; Zheng G; Wang W; Zhao Y; Wang X; Zhang Y Oncol Lett; 2022 Aug; 24(2):250. PubMed ID: 35761938 [TBL] [Abstract][Full Text] [Related]
4. ALDOB represents a potential prognostic biomarker for patients with clear cell renal cell carcinoma. Shao Y; Wu B; Yang Z; Liu Z; Ma Y; Huang H; Liu Y; Wang Z; Hu W; Wang Y; Niu Y Transl Androl Urol; 2023 Apr; 12(4):549-571. PubMed ID: 37181232 [TBL] [Abstract][Full Text] [Related]
5. N6-Methyladenosine-Related Long Non-coding RNA Signature Associated With Prognosis and Immunotherapeutic Efficacy of Clear-Cell Renal Cell Carcinoma. Ma T; Wang X; Wang J; Liu X; Lai S; Zhang W; Meng L; Tian Z; Zhang Y Front Genet; 2021; 12():726369. PubMed ID: 34721523 [TBL] [Abstract][Full Text] [Related]
6. The Role of Critical N6-Methyladenosine-Related Long Non-Coding RNAs and Their Correlations with Immune Checkpoints in Renal Clear Cell Carcinoma. Deng W; Wang G; Deng H; Yan Y; Zhu K; Chen R; Liu X; Chen L; Zeng T; Fu B Int J Gen Med; 2021; 14():9773-9787. PubMed ID: 34934351 [TBL] [Abstract][Full Text] [Related]
7. Contributions and Prognostic Values of N6-Methyladenosine RNA Methylation Regulators in Hepatocellular Carcinoma. Qi LW; Jia JH; Jiang CH; Hu JM Front Genet; 2020; 11():614566. PubMed ID: 33519919 [TBL] [Abstract][Full Text] [Related]
8. Identification and validation of m6A-associated ferroptosis genes in renal clear cell carcinoma. Pang S; Zhao S; Dongye Y; Fan Y; Liu J Cell Biol Int; 2024 Jun; 48(6):777-794. PubMed ID: 38440906 [TBL] [Abstract][Full Text] [Related]
9. An effective N6-methyladenosine-related long non-coding RNA prognostic signature for predicting the prognosis of patients with bladder cancer. Ma T; Wang X; Meng L; Liu X; Wang J; Zhang W; Tian Z; Zhang Y BMC Cancer; 2021 Nov; 21(1):1256. PubMed ID: 34802433 [TBL] [Abstract][Full Text] [Related]
10. Comprehensive Analysis of N6-Methyladenosine-Related IncRNAs Prognostic Signature and the Associated Immune Infiltrates in Kidney Renal Clear Cell Carcinoma. Chen X; Wang L; Tu J; Pan X; Li Y; Yin H; Wang M; Yuan X Crit Rev Eukaryot Gene Expr; 2022; 32(1):79-98. PubMed ID: 35377983 [TBL] [Abstract][Full Text] [Related]
11. Molecular Characterization of m6A Modifications in Non-Clear Cell Renal Cell Carcinoma and Potential Relationship with Pathological Types. Xiang X; Guo Y; Chen Z; Mo Z Int J Gen Med; 2022; 15():1595-1608. PubMed ID: 35210831 [TBL] [Abstract][Full Text] [Related]
12. Comprehensive Analysis of PD-L1 Expression, Immune Infiltrates, and m6A RNA Methylation Regulators in Esophageal Squamous Cell Carcinoma. Guo W; Tan F; Huai Q; Wang Z; Shao F; Zhang G; Yang Z; Li R; Xue Q; Gao S; He J Front Immunol; 2021; 12():669750. PubMed ID: 34054840 [TBL] [Abstract][Full Text] [Related]
13. Systematic analyses of the role of prognostic and immunological EIF3A, a reader protein, in clear cell renal cell carcinoma. Zhang Y; Hua X; Shi H; Zhang L; Xiao H; Liang C Cancer Cell Int; 2021 Dec; 21(1):680. PubMed ID: 34923969 [TBL] [Abstract][Full Text] [Related]
14. N6‑methyladenosine RNA methylation regulators participate in malignant progression and have prognostic value in clear cell renal cell carcinoma. Zheng Z; Mao S; Guo Y; Zhang W; Liu J; Li C; Yao X Oncol Rep; 2020 May; 43(5):1591-1605. PubMed ID: 32323803 [TBL] [Abstract][Full Text] [Related]
15. Decreased expression of METTL14 predicts poor prognosis and construction of a prognostic signature for clear cell renal cell carcinoma. Wang Y; Cong R; Liu S; Zhu B; Wang X; Xing Q Cancer Cell Int; 2021 Jan; 21(1):46. PubMed ID: 33430867 [TBL] [Abstract][Full Text] [Related]
16. Estimating the prognosis of esophageal squamous cell carcinoma based on The Cancer Genome Atlas (TCGA) of m6A methylation-associated genes. Pu Y; Lu X; Yang X; Yang Y; Wang D; Li M; Guan W; Xu M J Gastrointest Oncol; 2022 Feb; 13(1):1-12. PubMed ID: 35284129 [TBL] [Abstract][Full Text] [Related]
17. Identification of a N6-Methyladenosine (m6A)-Related lncRNA Signature for Predicting the Prognosis and Immune Landscape of Lung Squamous Cell Carcinoma. Weng C; Wang L; Liu G; Guan M; Lu L Front Oncol; 2021; 11():763027. PubMed ID: 34868980 [TBL] [Abstract][Full Text] [Related]
18. Molecular subtypes of m Guan B; Ren F; Shan W; Zhang S Transl Cancer Res; 2022 Mar; 11(3):508-518. PubMed ID: 35402182 [TBL] [Abstract][Full Text] [Related]
19. Effect of N6-methyladenosine (m6A) regulator-related immunogenes on the prognosis and immune microenvironment of breast cancer. Yu Z; He Q; Xu G Transl Cancer Res; 2022 Dec; 11(12):4303-4314. PubMed ID: 36644186 [TBL] [Abstract][Full Text] [Related]
20. Prognostic risk signature based on the expression of three m6A RNA methylation regulatory genes in kidney renal papillary cell carcinoma. Sun Z; Jing C; Xiao C; Li T; Wang Y Aging (Albany NY); 2020 Nov; 12(21):22078-22094. PubMed ID: 33177247 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]